Downregulation of MLL3 in esophageal squamous cell carcinoma is required for the growth and metastasis of cancer cells

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 605-613

  Xia, Manhui ^a   Xu, Lifang ^a   Leng, Yunhua ^a   Gao, Feng ^a   Xia, Hong ^a   Zhang, Diandian ^a   Ding, Xuewu ^a  

^a JINGJIANG PEOPLE'S HOSPITAL   (China)

Author keywords

Cancer metastasis; Cell proliferation; ESCC; MLL3

Indexed keywords

CYCLIN D1; MIXED LINEAGE LEUKEMIA 3 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; DNA BINDING PROTEIN; MLL3 PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CARCINOGENICITY; CELL GROWTH; CELL GROWTH ASSAY; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS; METHYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STABLE TRANSFECTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL MOTION; DRUG EFFECTS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SECOND CANCER; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEOPLASMS, SECOND PRIMARY;

EID: 84925497220     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2616-3     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
2. Wang N, Dong XJ, Zhou RM, Guo W, Zhang XJ, Li Y. An investigation on the polymorphisms of two DNA repair genes and susceptibility to ESCC and GCA of high-incidence region in northern China. Mol Biol Rep. 2009;6(2):357–64.
3. Vos M, Adams CH, Victor TC, van Helden PD. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet. 2003;140(1):23–30.
4. Kondo Y, Katsushima K, Ohka F, Natsume A, Shinjo K. Epigenetic dysregulation in glioma. Cancer Sci. 2012;105(4):363–9.
5. Suzuki H, Maruyama R, Yamamoto E, Kai M. Epigenetic alteration and microRNA dysregulation in cancer. Front Genet. 2014;4:258.
6. Stewart S, Tsun ZY, Izpisua Belmonte JC. A histone demethylase is necessary for regeneration in zebrafish. Proc Natl Acad Sci U S A. 2009;106(47):19889–94.
7. Litt M, Qiu Y, Huang S. Histone arginine methylations: their roles in chromatin dynamics and transcriptional regulation. Biosci Rep. 2009;29(2):131–41.
8. Li B, Liu HY, Guo SH, Sun P, Gong FM, Jia BQ. Mll3 genetic variants affect risk of gastric cancer in the Chinese Han population. Asian Pac J Cancer Prev. 2013;14(7):4239–42.
9. Morgan MA, Shilatifard A. Drosophila SETs its sights on cancer: Trr/MLL3/4 COMPASS-like complexes in development and disease. Mol Cell Biol. 2012;33(9):1698–701.
10. Li WD, Li QR, Xu SN, et al. Exome sequencing identifies an MLL3 gene germ line mutation in a pedigree of colorectal cancer and acute myeloid leukemia. Blood. 2012;121(8):1478–9.
11. Ansari KI, Hussain I, Kasiri S, Mandal SS. HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen via involvement of histone methylases MLL3 and MLL4. J Mol Endocrinol. 2012;48(1):61–75.
12. Watanabe Y, Castoro RJ, Kim HS, et al. Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS One. 2012;6(8):e23320.
13. Balakrishnan A, Bleeker FE, Lamba S, et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res. 2007;67(8):3545–50.
14. Lee J, Kim DH, Lee S, et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A. 2009;106(21):8513–8.
15. Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2013;509(7498):91–5.
16. Yamamoto H, Watanabe Y, Maehata T, et al. An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa. World J Gastroenterol. 2013;20(14):3927–37.
17. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44(5):570–4.
18. Ashktorab H, Schaffer AA, Daremipouran M, Smoot DT, Lee E, Brim H. Distinct genetic alterations in colorectal cancer. PLoS One. 2012;5(1):e8879.
19. Adham SA, Al Harrasi I, Al Haddabi I, et al. Immunohistological insight into the correlation between neuropilin-1 and epithelial mesenchymal transition (EMT) markers in epithelial ovarian cancer (EOC). J Histochem Cytochem. 2012;62(9):619–31.
20. Cui Y, Chang D, Liu M, et al. Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2012;11:266.
21. Gonzaga IM, Soares-Lima SC, de Santos PT, et al. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer. 2012;12:569.
22. Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res. 2009;315(4):572–82.
23. Wu X, Zhang J, Zhen R, et al. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. J Transl Med. 2012;10:180.
24. Hara F, Aoe M, Doihara H, et al. Antitumor effect of gefitinib (‘Iressa’) on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett. 2005;226(1):37–47.
25. Wang C, Guo LB, Ma JY, Li YM, Liu HM. Establishment and characterization of a paclitaxelresistant human esophageal carcinoma cell line. Int J Oncol. 2012;43(5):1607–17.
26. Forghanifard MM, Moaven O, Farshchian M, et al. Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis. Ann Surg Oncol. 2012;19(3):743–9.
27. Jin H, Morohashi S, Sato F, et al. Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. Biomed Res. 2012;31(2):105–12.
28. Natsugoe S, Uchikado Y, Okumura H, et al. Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep. 2007;17(3):517–23.